[Enterosan--perspective medications for patients with postinfection irritable bowel syndrome]

Eksp Klin Gastroenterol. 2011:(3):102-4.
[Article in Russian]


The pathogenesis of PIBS matter transferred intestinal infections that lead to persistent intestinal dysbiosis. The aim of this study was to investigate the effectiveness of enterosana at PIBS.

Materials and methods: A total of 37 patients with PIBS diarrhea included in the study group and 30 patients consisted the control group. Diagnosis PIBS installed in accordance with the criteria of the Rome Consensus II. To assess the intestinal microflora were sown feces and made hydrogen breath test.

Results: In the study group patients by the end of the 3-week course enterosan therapy was appeared stable clinical PIBS remission. In the reseeding of feces decreased levels of conditionally pathogenic microflora and increased to normal number of bifidobacteria and lactobacilli. Were normalized rates of hydrogen in exhaled air according to breath test, which reflects bacterial overgrowth in the lumen of the small intestine.

Conclusion: Enterosan has good therapeutic effect in treating patients with PIBS, helps to restore normal intestinal microflora and improve intestinal digestion.

Publication types

  • Clinical Trial
  • English Abstract

MeSH terms

  • Adult
  • Breath Tests
  • Diarrhea / complications*
  • Diarrhea / microbiology
  • Feces / microbiology
  • Female
  • Glycosaminoglycans / administration & dosage
  • Glycosaminoglycans / therapeutic use*
  • Humans
  • Intestinal Mucosa / drug effects
  • Intestinal Mucosa / microbiology
  • Intestine, Small / drug effects
  • Intestine, Small / microbiology*
  • Irritable Bowel Syndrome / drug therapy*
  • Irritable Bowel Syndrome / etiology
  • Irritable Bowel Syndrome / microbiology
  • Male
  • Treatment Outcome
  • Young Adult


  • Glycosaminoglycans
  • enterosan